Home » Stocks » CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. (CASI)

Stock Price: $1.92 USD -0.02 (-1.03%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 237.92M
Revenue (ttm) 10.21M
Net Income (ttm) -46.30M
Shares Out 123.92M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $1.92
Previous Close $1.94
Change ($) -0.02
Change (%) -1.03%
Day's Open 1.97
Day's Range 1.91 - 2.00
Day's Volume 325,442
52-Week Range 1.15 - 3.82

More Stats

Market Cap 237.92M
Enterprise Value 183.42M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 123.92M
Float 62.69M
EPS (basic) -0.48
EPS (diluted) -0.40
FCF / Share -0.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.72M
Short Ratio 9.48
Short % of Float 2.61%
Beta 0.92
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23.31
PB Ratio 3.35
Revenue 10.21M
Operating Income -47.40M
Net Income -46.30M
Free Cash Flow -29.01M
Net Cash 54.50M
Net Cash / Share 0.44
Gross Margin 1.92%
Operating Margin -464.38%
Profit Margin -614.30%
FCF Margin -284.19%
ROA -22.31%
ROE -39.94%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.50*
Low
3.50
Current: $1.92
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4.13---0.050.02-0.671.943.69
Revenue Growth----101.09%---65.52%-47.45%-
Gross Profit0.20---0.040.02-0.671.943.69
Operating Income-46.96-27.19-10.75-9.42-7.15-26.19-5.74-4.50-4.57-7.53
Net Income-46.03-27.47-10.77-9.45-7.21-26.20-5.74-14.55-4.56-8.10
Shares Outstanding95.9584.7561.5155.8732.4528.6026.1319.0611.789.68
Earnings Per Share-0.48-0.32-0.18-0.17-0.22-0.92-0.22-0.78-0.47-0.94
Operating Cash Flow-23.24-28.58-6.40-6.02-5.51-4.00-3.28-2.21-4.27-4.96
Capital Expenditures-7.05-1.13-0.93-0.06-0.03-0.23-0.04-0.050.05-
Free Cash Flow-30.30-29.71-7.34-6.09-5.54-4.23-3.32-2.26-4.22-4.96
Cash & Equivalents54.2585.1243.4927.095.1310.6715.138.051.084.91
Total Debt-1.501.501.491.461.39---0.76
Net Cash / Debt54.2583.6241.9925.603.679.2815.138.051.084.15
Assets10311345.1027.715.8311.3115.518.983.248.04
Liabilities8.973.956.566.9311.9111.730.570.740.702.70
Book Value73.0010938.5420.78-6.09-0.4214.948.242.535.33
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CASI Pharmaceuticals, Inc.
Country United States
Employees 125
CEO Wei-Wu He

Stock Information

Ticker Symbol CASI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CASI
IPO Date June 11, 1996

Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.